Fernandez-Cuesta will conduct the first molecular characterization of a new aggressive pulmonary carcinoid subtype called supra-carcinoids to identify potential drug targets for treating this disease.
What question will the researchers try to answer?
What are the molecular underpinnings of supra-carcinoids, a new aggressive subtype of NETs with a poor outlook, and what opportunities exist to interrupt cellular pathways to stop or slow tumor growth?
Why is this important?
The molecular characteristics of lung NETs are mostly unknown. To date, there is no explanation of why some cases grow slowly, and others very aggressively. Understanding the characteristics of aggressive lung NETs will help find screening and treatment approaches and better care for patients with the highest risks.
What will researchers do?
Researchers will molecularly characterize lung supra-carcinoids to look for opportunities to slow and stop tumor growth. By generating laboratory models that mimic the growth of supra-carcinoids, they will establish a valuable resource for continued study of this new lung NET subtype. Any diagnostic and therapeutic biomarkers identified will be validated by researchers.
How might this improve the treatment of NETs?
This study will better inform the clinical management of lung NETs to improve the survival of patients and to identify those at highest risk for relapse. Initial research by Fernandez-Cuesta and colleagues showed supra-carcinoids had a high expression of immune checkpoint genes. These experiments will further explore the potential of immunotherapy.
What is the next step?
The laboratory models established in this study will serve as a valuable platform for future preclinical testing of specific drugs to treat supra-carcinoids. In addition, the molecular profiling data generated will inform future research on how supra-carcinoids develop and grow.